Download Files:
JNJ-55308942
$210 – $1,400
Products Details
Product Description
– JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC50=10 nM, Ki=7.1 nM; rP2X7: IC50=15 nM, Ki=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain[1][2].
Web ID
– HY-123857
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H12F5N7O
References
– [1]Bhattacharya A, et al. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology. 2018;43(13):2586-2596.|[2]Chrovian CC, et al. A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate. J Med Chem. 2018;61(1):207-223.
CAS Number
– 2166558-11-6
Molecular Weight
– 425.32
Compound Purity
– 99.95
SMILES
– O=C(C1=C(F)C(C(F)(F)F)=NC=C1)N2[C@@H](C)CC(N(C3=NC=C(F)C=N3)N=N4)=C4C2
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– P2X Receptor
Isoform
– P2X7 Receptor
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
